Cardiocomm Solutions Participates in Ontario Trade Mission to Japan and Korea

New Software and Device Technology Innovations for Remote Patient Monitoring Highlighted

Toronto, Ontario--(Newsfile Corp. - February 22, 2018) - **CardioComm Solutions, Inc.** ("CardioComm" or the "Company") (TSXV: EKG) is participating in a series of meetings organized by the Ontario Trade Commission in partnership with Global Affairs Canada which has led to a delegation visit to Japan and Korea from February 20th to 27th.

Through the assistance of the Trade Commission, meetings were held in November 2017 with visiting Japanese hospital representatives in Toronto in advance of CardioComm's visit to Japan. While in Japan and Korea, CardioComm has meetings set with additional hospital/medical groups and will have a booth presence in the Ontario Pavilion during the *Medical Japan 2018 International Medical Expo & Conference*. Medical Japan (www.medical-jpn.jp/en/) is one of the most important healthcare shows in Japan and was visited by over 29,000 visitors from the hospital, manufacturing, importation and distributors sectors in 2017. The Company confirms that during the exposition discussions on distribution opportunities in Japan, Korea, Singapore and Thailand will be held.

CardioComm is actively evaluating the Japanese, Korean and other regional markets for the clearance and sales of its newest HeartCheck™ ECG monitoring devices and introduction of its GEMS™ based SMART Monitoring ECG service. CardioComm's visit to Japan is at an opportune time as there have been directives issued from a panel under the Japanese Health, Labor and Welfare Ministry introducing new medical fee reimbursements related to the implementation of telemedicine platforms. Effective April 1, 2018, new fees for doctors offering counseling over the internet, as well as for telemedicine based services, will take effect including a fee for mobile ECG monitoring at a value of 1500 JPY (approximately Cdn$18) per ECG. The Japanese government has also revised the medical device regulatory review process to shorten and standardize the review time for medical device approval which will help foreign medical device companies to get their products on the Japanese market sooner. CardioComm itself has almost 20 years of Class II medical device clearances with Health Canada and the FDA and will have ISO 13485:2016 under MDSAP which will facilitate such regulatory review.

According to the Ontario Ministry of International Trade, Japan is the world's 3rd largest medical market with high stability and valued at US$527 billion. Their ever increasing rate of aged population drives the medical needs for cost effective solutions for medical monitoring the elderly ay home. In addition, the Japanese medical device market relies heavily on imported products with imported medical devices accounting for 49% of the devices used. In its first four days of meetings the Company has received interest from several organizations looking to capitalize on the new regulations related to remote patient monitoring and telemedicine. These groups are seeking a credible and proven ECG management platform for providing remote ECG monitoring services to hospitals and private patient care management groups. CardioComm's ECG management software is well recognized as a proven telemedicine platform capable of managing one to 12 lead ECG monitoring devices with ECG recording durations ranging from 30 days of continuous recordings to 30 seconds. Greatest interest has been shown in Bluetooth connected hand held ECG devices as well as wearable 12 lead ECG technologies, both of which CardioComm is well supported for by well establish relationships with device manufacturers. CardioComm is also looking for new ECG monitoring hardware technologies developed in Japan for introduction under the HeartCheck™ brand into the North American markets.

To learn more about the CardioComm Solutions' products, please see the Company's websites www.theheartcheck.com and www.cardiocommsolutions.com.

About CardioComm Solutions

CardioComm Solution's patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. CardioComm Solutions is cleared by the FDA for the sales of a consumer based HeartCheck™ PEN handheld EKG device and home version of its proprietary GEMS™ Home software. Products are sold worldwide through a combination of an external distribution networks and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant and has received FDA market clearance for its software and devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada.

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com
investor.relations@cardiocommsolutions.com
www.cardiocommsolutions.com

Forward-looking statements
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information

involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (*Continuous Disclosure Obligations*).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.